Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SRZN vs MNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Captures Overall Composite Edge (36.0 SELL vs 50.2 HOLD), While MNOV Leads 3–2 on Growth & Valuation Pillars

SRZN Overall Winner 6-Pillar Tally: SRZN 2 – 3 MNOV (1 Tie) Matrix Metrics: SRZN 4 – 5 MNOV

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Medicinova, Inc. (MNOV) on higher Unified Composite conviction (36.0/100 SELL vs. 50.2/100 HOLD) after splitting the core matrix 4–5 (led by Growth & Scale, Options & Positioning), while MNOV wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $28.46 (N/M Forward P/E, -485.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin).

  • Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1232.2% operating margin) and revenue trajectory (+408.6% vs. +12.4% YoY).
  • Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs MNOV
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 MNOV)

Columns: Metric · SRZN · MNOV
1. Valuation Multiples MNOV
Forward P/E N/M 8.5x
Trailing P/E N/M 8.5x
PEG Ratio N/M N/M
EV / Revenue 52.1x 42.5x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +12.4%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $935,717
Market Cap $642.7M $65.1M
3. Profitability & Quality MNOV
Gross Margin N/A 42.2%
Operating Margin -485.4% -1232.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -24.8%
4. Balance Sheet & Cash Flow MNOV
Cash Generation (TTM) -$31M -$9.1M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $25M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (13th %ile) 140.1% (50th %ile)
Put/Call OI Skew 21.00x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (4) vs MNOV (5)
Institutional Metric SRZN MNOV Criterion Row Edge
Market Capitalization
Scale
$642.7M $65.1M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY)
Growth
+408.6% +12.4% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -1232.2% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -24.8% Higher ROE MNOV
52-Week Range Position
Momentum
63% ($13–$38) 3% ($1–$4) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.29β · 73% Vol 0.59β · 38% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 50.2 / 100 (HOLD) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
$11M $935,717 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 52.1x EV/Rev N/M PEG · 42.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$9.1M ($25M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +17.61 pp
SRZN: +10.52% · MNOV: -7.09%
3M Horizon SRZN +33.11 pp
SRZN: +18.73% · MNOV: -14.38%
6M Horizon SRZN +14.36 pp
SRZN: +7.93% · MNOV: -6.43%
1Y Horizon SRZN +119.2 pp
SRZN: +110.81% · MNOV: -8.39%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue MNOV Revenue SRZN Op. Margin MNOV Op. Margin Margin Leader
FY2012 N/A $0M N/A -1363.8% MNOV
FY2021 N/A $0M N/A -253.0% MNOV
FY2022 $10M N/A -354.7% N/A SRZN
FY2023 N/A $0M N/A -990.0% MNOV
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M $0M -1210.6% -3242.5% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs MNOV Key Questions & Quantitative Answers

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Medicinova, Inc. (MNOV) on higher Unified Composite conviction (36.0/100 SELL vs. 50.2/100 HOLD) after splitting the core matrix 4–5 (led by Growth & Scale, Options & Positioning), while MNOV wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $28.46 (N/M Forward P/E, -485.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1232.2% operating margin) and revenue trajectory (+408.6% vs. +12.4% YoY). Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). Across the 6-period historical trajectory (FY2012 to FY2025), SRZN cumulative revenue shifted +0.0% while MNOV shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.

MNOV screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus MNOV (-24.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.